(Total Views: 294)
Posted On: 03/30/2021 4:19:09 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and time-consuming to collect. “The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer,” reads a recent article discussing the company’s positioning. “The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and time-consuming to collect. “The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer,” reads a recent article discussing the company’s positioning. “The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
